New guidelines cover pharmacologic therapy in obesity
Investigators at the American College of Physicians have introduced new clinical guidelines on the use of pharmacologic treatments in adult patients with overweight or obesity.
In a study published in the Annals of Internal Medicine, the investigators conducted a systematic review and network meta-analysis focused on drugs used to manage overweight and obesity among nonpregnant adult patients in outpatient settings. They subsequently developed two recommendations using evidence from the Ovid MEDLINE ALL, Cochrane Central Register of Controlled Trials, CINAHL and Embase databases.
The investigators advised clinicians to prescribe semaglutide and tirzepatide as first-line treatments, phentermine-topiramate as a second-line treatment, liraglutide as a third-line treatment and naltrexone-bupropion as a fourth-line treatment in addition to lifestyle modifications in those with a body mass index of 30 or higher. Patients with comorbidities such as Type 2 diabetes, cardiovascular disease, dyslipidemia, hypertension or sleep apnea whose BMI is 27 to 30 should receive semaglutide and tirzepatide as first-line treatment and liraglutide as second-line treatment.
The investigators emphasized that the potential benefits and risks of treatment should be discussed with patients prior to the initiation or changing of pharmacologic therapy in patients with obesity or overweight.
Read more: Annals of Internal Medicine
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.